[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
February 14, 2007

Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary SyndromesQuestions, Answers, and More Questions

Author Affiliations
 

Author Affiliations: Duke Clinical Research Institute, Duke Translational Medicine Institute, Durham, NC.

JAMA. 2007;297(6):636-639. doi:10.1001/jama.297.6.636

Contemporary management of acute coronary syndromes (ACS) has advanced in the past decade because of synergies between the tenets of basic science and findings from clinical trials.1 Clinicians, clinical investigators, and patients depend on definitive evidence to promote changes in clinical care. The current challenge is to create a clinical research system that responds to changes in the science with rapid and efficient planning of studies, acquisition of data, analysis, and dissemination of information. Such a system can provide the foundation for continued improvement in clinical care.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×